Where Will Syncom Formulations (India) Share Price Be in the Next 3 Years?

The Syncom Formulations (India) share price outlook for the next 3 years is a question on many investors' minds as the stock trades at Rs 13.1, within a 52 week range of Rs 10.21 to Rs 18.93. This article lays out a scenario based Syncom Formulations (India) share price outlook for 2027, 2028 and 2030, built on the company's fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Syncom Formulations (India) Company Overview

Syncom Formulations (India) is a Pithampur (Madhya Pradesh) based WHO-GMP certified generic pharmaceutical manufacturer with more than 500 formulation products spanning tablets, injectables and dry syrups sold across 15-plus countries. Understanding the business model is the first step in framing any credible Syncom Formulations (India) share price outlook, because the durability of earnings ultimately decides where the stock trades.

Company	Syncom Formulations (India)
NSE Ticker	SYNCOMF
Sector	Generic Pharmaceuticals
CMP	Rs 13.1
52 Week High	Rs 18.93
52 Week Low	Rs 10.21
Market Cap	Rs 1,248 Cr
Stock PE	16.4

Where Does Syncom Formulations (India) Share Price Stand Today?

The stock currently trades about 31 percent below its 52 week high of Rs 18.93, which means the market has already priced in some caution. For anyone building a Syncom Formulations (India) share price outlook, this starting point matters, because entry valuations have a large bearing on 3 year returns.

At the current price, Syncom Formulations (India) commands a market capitalisation of Rs 1,248 Cr and trades at a price to earnings multiple of 16.4. These figures anchor the Syncom Formulations (India) share price outlook scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

Syncom Formulations (India) Share Price Outlook: Key Growth Drivers for the Next 3 Years

A handful of forces are likely to shape the Syncom Formulations (India) share price outlook between now and 2030, and together they explain most of the dispersion in this Syncom Formulations (India) share price outlook. Each is discussed below with its likely direction of impact.

Capacity Expansion and Product Approvals

Stock prices ultimately follow earnings. The company has delivered a healthy 21% five year profit CAGR while remaining almost debt free. The pace at which this plays out over FY27 to FY30 will be one of the biggest determinants of the Syncom Formulations (India) share price outlook actually materialising.

Healthcare and Life Sciences Demand

Syncom Formulations (India) operates in the generic pharmaceuticals space, where sector-wide demand and pricing cycles influence how investors value the stock. Structural tailwinds in this segment, if sustained, support the more optimistic end of the Syncom Formulations (India) share price outlook.

Company Specific Catalysts

Expansion into injectables and critical care manufacturing is the stated growth lever management is pursuing. If this plays out on schedule, the Syncom Formulations (India) share price outlook for 2030 could gravitate toward the upper end of the scenario range discussed below.

Macro Environment and Liquidity

The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay for Syncom Formulations (India). A benign macro backdrop supports the optimistic end of this Syncom Formulations (India) share price outlook, while global risk aversion would do the opposite.

Syncom Formulations (India) Share Price Outlook 2027, 2028 and 2030: Scenario Analysis

The table below presents a scenario based Syncom Formulations (India) share price outlook using compounded growth assumptions applied to the current market price of Rs 13.1. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.

Year	Bear Case	Base Case	Bull Case	Assumption
2027	Rs 13.1	Rs 15.1	Rs 17.2	0% to 20% CAGR on CMP
2028	Rs 13.1	Rs 16.6	Rs 20.7	0% to 20% CAGR on CMP
2030	Rs 13.1	Rs 20.1	Rs 29.8	0% to 20% CAGR on CMP

In the base case scenario of this Syncom Formulations (India) share price outlook, the 2030 level works out to roughly Rs 20.1, implying steady compounding from today's levels. The bull case of Rs 29.8 plays out if expansion into injectables and critical care manufacturing is the stated growth lever management is pursuing, which would let both earnings and the valuation multiple re-rate higher, while the bear case of Rs 13.1 captures a scenario where growth stalls. That is an outcome band of about 0 percent to 127 percent over the period.

Consult a SEBI Registered Investment Advisor Before Acting on Any Projection

Bull Case vs Bear Case for Syncom Formulations (India) Share Price

The Bull Case

The optimistic Syncom Formulations (India) share price outlook assumes expansion into injectables and critical care manufacturing is the stated growth lever management is pursuing. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 29.8 by 2030.

The Bear Case

The cautious view centres on the fact that as a small, low priced pharma stock, liquidity and single-facility concentration risk are worth watching alongside regulatory compliance costs. If these pressures dominate, the Syncom Formulations (India) share price outlook would skew toward the lower band and the stock could stagnate near Rs 13.1 even by 2030, underperforming broader indices.

Key Risks That Could Change the Syncom Formulations (India) Share Price Outlook

• Execution risk: Delays in scaling operations, branch or capacity expansion, or new business lines could push the earnings trajectory below the base case.
• Valuation risk: At the current earnings multiple, any disappointment on profit growth can trigger sharp multiple compression before fundamentals stabilise.
• Sector risk: As a small, low priced pharma stock, liquidity and single-facility concentration risk are worth watching alongside regulatory compliance costs.
• Macro risk: A global or domestic slowdown, adverse FII flows or unexpected rate moves would compress equity valuations broadly, including for this stock.
• Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little advance warning.

Is Syncom Formulations (India) Worth Watching for the Long Term?

For long term investors, the relevant question is not just where the Syncom Formulations (India) share price outlook lands in 2030 or what any single Syncom Formulations (India) share price outlook says today, but whether the business can compound capital through cycles. The company has delivered a healthy 21% five year profit CAGR while remaining almost debt free. That gives Syncom Formulations (India) a credible story to track, while the risks outlined above define what must be monitored each quarter.

Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Syncom Formulations (India) share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.

Download the Univest iOS App or Univest Android App to track Syncom Formulations (India) share price live.

Conclusion

The Syncom Formulations (India) share price outlook for the next 3 years spans Rs 13.1 to Rs 29.8 by 2030 under the scenarios discussed, with a base case near Rs 20.1. Any credible Syncom Formulations (India) share price outlook must be updated as facts change, and the path will be decided by earnings delivery, sector conditions and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.

FAQs on Syncom Formulations (India) Share Price Outlook

What is the Syncom Formulations (India) share price outlook for the next 3 years?

Ans. The Syncom Formulations (India) share price outlook for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 13.1 in the bear case to Rs 29.8 in the bull case, with a base case near Rs 20.1, depending on earnings delivery and market conditions.

What is the future of Syncom Formulations (India) share price?

Ans. The future of Syncom Formulations (India) share price depends largely on how the company executes against its growth drivers over FY27 to FY30, alongside sector conditions and the broader market environment. Historically, businesses that deliver consistent earnings tend to see steadier price outcomes over such horizons.

What is the Syncom Formulations (India) share price outlook for 2027?

Ans. For 2027, the scenario range works out to roughly Rs 13.1 to Rs 17.2, with a base case around Rs 15.1. This is illustrative and not a guaranteed outcome, and actual prices will depend on quarterly results and market sentiment.

What is the Syncom Formulations (India) share price projection for 2030?

Ans. The Syncom Formulations (India) share price projection for 2030 spans Rs 13.1 to Rs 29.8 across the bear and bull scenarios discussed in this article, with the base case near Rs 20.1. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What is the current share price of Syncom Formulations (India)?

Ans. Syncom Formulations (India) currently trades at around Rs 13.1 on the NSE, within a 52 week range of Rs 10.21 to Rs 18.93. Prices change continuously during market hours, so check live quotes before acting.

Is Syncom Formulations (India) a good stock for the long term?

Ans. Syncom Formulations (India) has a growth story worth watching: the company has delivered a healthy 21% five year profit CAGR while remaining almost debt free. At the same time it carries risks, since as a small, low priced pharma stock, liquidity and single-facility concentration risk are worth watching alongside regulatory compliance costs. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What are the key risks to the Syncom Formulations (India) share price outlook?

Ans. The main risks are execution delays, valuation compression if earnings disappoint, sector-specific pressures, macro shocks such as adverse FII flows or rate moves, and regulatory or policy changes. Any of these can push the stock below the base case scenario discussed in this article.